digoxin / Generic mfg. - LARVOL DELTA

THE SECOND ACT: RECURRENCE OF ATRIAL TACHYCARDIA AFTER SUCCESSFUL ATRIAL FLUTTER CARDIOVERSION (WRMC 2026) - "This persisted despite treatment with sequential maternal antiarrhythmic therapy (sotalol, digoxin, flecainide)...AET was successfully treated with esmolol and then sotalol. Heart failure was treated with milrinone and cardiac function gradually recovered over the next 6 days (LVEF 60%)...This challenges our understanding of atrial flutter as a standalone arrhythmia and emphasizes the need for extended cardiac monitoring beyond the conventional post-cardioversion observation period in high-risk infants. Newborn's ECG Showing Atrial Ectopic Tachycardia at 48 Hours of Life"

Cardiovascular • Congestive Heart Failure • Heart Failure

Development and Validation of a UHPLC-MS/MS Method to Identify Interference from Qiliqiangxin Capsule and Deslanoside in Digoxin Therapeutic Drug Monitoring: A Comparison with Immunoassay. (PubMed, Ther Drug Monit) - "The developed UHPLC-MS/MS method was highly sensitive and time-efficient, making it a reliable tool for digoxin TDM and identifying interference from Qiliqiangxin capsule and deslanoside."

Journal

Dicloxacillin and Flucloxacillin Inhibit Hepatic Uptake Transporters-In Vitro Investigations and Physiologically Based Pharmacokinetic Modeling. (PubMed, Clin Transl Sci) - "PBPK model simulations predicted no major change in rosuvastatin, a substrate for OATPs and BCRP, pharmacokinetics when co-administered with dicloxacillin or flucloxacillin. Simulations with dicloxacillin and P-gp substrates dabigatran or digoxin also predicted limited inhibition of P-gp transport."

Journal • PK/PD data • Preclinical • Breast Cancer • Oncology • Solid Tumor • SLCO2B1

Magnetic C18-modified mesoporous silica as an efficient adsorbent for dispersive solid phase microextraction of cardiac glycosides in human plasma. (PubMed, J Chromatogr A) - "In addition, an absence of matrix effect was observed for the proposed method when applied to human plasma, while satisfactory lower limits of quantification (8 ng/mL for deslanoside and 1.6 ng/mL for lanatoside C, digoxin and digitoxin) and stability were obtained. Overall, owing to its simplicity, efficiency, quickness and eco-friendliness, the developed method serves as a promising alternative for determining cardiac glycosides in complex biological matrices."

Journal

Study to Evaluate the Effect of Repotrectinib on the Drug Levels of Transporter and CYP P450 Probe Substrates in Healthy Adult Participants (clinicaltrials.gov) - P1 | N=32 | Recruiting | Sponsor: Bristol-Myers Squibb | Not yet recruiting ➔ Recruiting

Enrollment open

Digoxin In Rheumatic Heart Disease: A Multi-center, Randomized, Double Blind, Placebo-controlled Trial (ACC 2026) - "Abstract is embargoed at this time."

Clinical • Late-breaking abstract • Cardiovascular • Heart Failure

ARTIFICIAL INTELLIGENCE-ENABLED ELECTROCARDIOGRAM ANALYSIS TO DETECT DIGOXIN EXPOSURE AND TOXICITY (ACC 2026) - "Abstract is embargoed at this time."

EVALUATION OF INTRAVENOUS DIGOXIN LOADING DOSES AFTER IMPLEMENTATION OF A STANDARDIZED ORDER PANEL (ACC 2026) - "Abstract is embargoed at this time."

Physiologically Based Pharmacokinetic Modeling of Digoxin in Adult and Pediatric Patients with Heart Failure. (PubMed, Pharmaceutics) - "It also pointed out the shortage of empirical dosing regimens for such a drug with a narrow therapeutic window. The model may assist in optimizing the pediatric dosing strategies of digoxin, and suggests that current neonatal dosing regimens need refinement."

Journal • PK/PD data • Cardiovascular • Congestive Heart Failure • Heart Failure • Pediatrics

EFFECT OF DIGOXIN ON MORTALITY IN HEART FAILURE PATIENTS RECEIVING GUIDELINE-DIRECTED MEDICAL THERAPY WITHOUT ATRIAL FIBRILLATION (ACC 2026) - "Abstract is embargoed at this time."

Clinical • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Heart Failure

HIDDEN IN PLAIN SIGHT: DIGOXIN TOXICITY MASKED ON ECG WITH ICD PACING (ACC 2026) - "Abstract is embargoed at this time."

Cardiovascular

WHEN DIGIFAB ISN’T ENOUGH: SUCCESSFUL RESCUE WITH PLASMAPHERESIS IN SEVERE DIGOXIN TOXICITY (ACC 2026) - "Abstract is embargoed at this time."

Cardiovascular

AN UNLUCKY NUT: HIGH-DOSE DIGOXIN IMMUNE FAB FOR SEVERE CARDIOTOXICITY AFTER POISONOUS INGESTION (ACC 2026) - "Abstract is embargoed at this time."

Cardiovascular

Repurposing the cardiac glycoside digoxin as a targeted treatment for SMARCA4-mutant ovarian cancer (LCC 2026) - "The pan-cancer analysis identified K-Strophanthidin as the top predicted candidate (adjusted p=0.00385). K-Strophanthidin was investigated previously for cardiovascular disease but replaced by digoxin, another cardiac glycoside with superior bioavailability. Digoxin was approved by the FDA in 1954 and TGA in 1991 to treat heart failure."

Congestive Heart Failure • Heart Failure • Oncology • Ovarian Cancer • Solid Tumor • SMARCA4

Comparative effectiveness of pharmacotherapy for heart failure with preserved ejection fraction: A systematic review and network meta-analysis. (PubMed, Diabetes Obes Metab) - "In patients with HFpEF, GLP-1RA, SGLT2i and MRA significantly reduced the risk of cardiovascular death and HF hospitalisation, while GLP-1RA additionally improved the functional and quality-of-life outcomes. GLP-1RA and SGLT2i significantly reduced HF morbidity, and GLP-1RA uniquely improved functional status, positioning adiposity modulation as a central therapeutic target in HFpEF."

HEOR • Journal • Retrospective data • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure • Obesity

Availability of emergency drugs and essential resuscitation equipment and associated barriers in Addis Ababa Health Centers, Ethiopia: a mixed-methods study. (PubMed, Afr J Emerg Med) - "While oxygen delivery devices and infection control materials were widely available, critical equipment and essential medications like crash carts, defibrillators, digoxin, and sodium bicarbonate were largely absent...The readiness of health centers to provide emergency care in Addis Ababa is inadequate, largely due to resource shortages and systemic barriers. Urgent interventions are needed to improve emergency preparedness at the primary care level, including provision of crash carts, investment in staff training, and revision of procurement and policy frameworks."

Journal • Infectious Disease

Drug-durg Interaction of RAY1225 With Warfarin, Atorvastatin, Metformin and Digoxin (clinicaltrials.gov) - P1 | N=32 | Active, not recruiting | Sponsor: Guangdong Raynovent Biotech Co., Ltd

New P1 trial • Genetic Disorders • Obesity

A Phase 1 Study of PROT-001. (clinicaltrials.gov) - P1 | N=124 | Completed | Sponsor: Protego Biopharma Pty Ltd | Recruiting ➔ Completed

First-in-human • Trial completion

Digoxin Attenuates Ocular Hypertension and Protects Trabecular Meshwork Cells via Ferroptosis Inhibition. (PubMed, Invest Ophthalmol Vis Sci) - "Digoxin significantly attenuated H2O2-induced ferroptosis in HTMCs by reducing MDA and restoring GPX4, ultimately lowering IOP in COH eyes. Our findings establish digoxin as a promising therapeutic agent that suppresses ferroptosis and reduces IOP via the SLC2A3/SCD/HBA1 pathway, providing a transformative strategy for POAG treatment."

Journal • Cardiovascular • Glaucoma • Ophthalmology • GPX4 • SLC2A3

The impact of delayed evacuation on the quality of human fetal tissue. (PubMed, PLoS One) - "Warm ischemia following circulatory arrest is the principal driver of tissue degradation, with RNA and cell viability most affected and DNA relatively preserved. Digoxin alone has minimal effect but accelerates degradation under warm conditions. Minimizing the interval between circulatory arrest and evacuation, and avoiding prolonged exposure to body temperature, may preserve tissue integrity and improve the diagnostic and research utility of HFT."

Journal • Cardiovascular

Digoxin for reduction of circulating tumor cell cluster size in metastatic breast cancer: a proof-of-concept trial. (PubMed, Nat Med) - P1 | "Thus, our data provide a first-in-human proof of principle that digoxin treatment leads to a partial CTC cluster dissolution, encouraging larger follow-up studies with refined Na+/K+ ATPase inhibitors and that include clinical outcome endpoints. ClinicalTrials.gov identifier: NCT03928210 ."

Circulating tumor cells • Journal • Breast Cancer • Oncology • Solid Tumor

RaP-AF: Rate Control in Patients With Atrial Fibrillation (clinicaltrials.gov) - P=N/A | N=13 | Completed | Sponsor: National Taiwan University Hospital | Active, not recruiting ➔ Completed | N=50 ➔ 13

Enrollment change • Trial completion • Atrial Fibrillation • Cardiovascular

Effect of Estrogen Treatment on Drug Metabolism and Transport (clinicaltrials.gov) - P4 | N=22 | Completed | Sponsor: University of Washington | N=13 ➔ 22 | Trial completion date: Jun 2026 ➔ Jul 2025 | Trial primary completion date: Jan 2026 ➔ Jul 2025 | Active, not recruiting ➔ Completed

Enrollment change • Trial completion • Trial completion date • Trial primary completion date

Identification of multiple cardiotonic steroids in faecal material of untreated humans and rat strains. (PubMed, Steroids) - "Multiple CTSs were detected in faecal material of untreated rats and humans Steroids varied between rat strains and aligned with phenotype. Extraction requires further solvent optimisation and the use of tandem MS/MS is essential to reliably detect the profile of CTSs present. Analysis of CTSs present in readily available faecal material will enable studies to determine relationships between CTSs, the microbiome and disease progression."

Journal • Preclinical • Cardiovascular • CTSS

The DIGIT-HF trial and the Mihai Gheorghiade legacy: time to reconsider cardiac glycosides as effective therapy in HFrEF. (PubMed, Heart Fail Rev) - "Digitoxin is a cardiac glycoside that differs from digoxin through its hepatic clearance and more stable pharmacokinetics, diminishing the impact of renal dysfunction and serum concentration fluctuations, thereby improving safety and facilitating long-term use in routine care. Here, we critically discuss in the context of available evidence the findings of the recently published DIGIT-HF (Digitoxin to Improve Outcomes in Patients with Advanced Chronic Heart Failure) trial, which for the first time evaluated the efficacy and safety of digitoxin in contemporary patients with HFrEF."

Journal • Review • Cardiovascular • Congestive Heart Failure • Heart Failure • Nephrology • Renal Disease